Dynavax Technologies reported $106.34M in Operating Expenses for its third fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Operating Expenses Change
Abbvie ABBV:US USD 10.21B 1.08B
Adma Biologics ADMA:US USD 18.97M 24.11M
Agenus AGEN:US USD 64.42M 1.07M
Amgen AMGN:US USD 4.61B 695M
AstraZeneca AZN:LN USD 9.74B 495M
Astrazeneca AZN:US USD 9.74B 495M
Biogen BIIB:US USD 1.19B 1.45B
Biomarin Pharmaceutical BMRN:US USD 507.76M 13.12M
Bristol Myers Squibb BMY:US USD 9.46B 716M
Chimerix CMRX:US USD 20.91M 2.98M
Dynavax Technologies DVAX:US USD 106.34M 21.9M
Gilead Sciences GILD:US USD 5.12B 917M
Glaxosmithkline GSK:US GBP 5.51B 1.13B
Idera Pharmaceuticals IDRA:US USD 9.33M 3.96M
Merk MRK:US USD 10.32B 624M
Minerva Neurosciences NERV:US USD 5.21M 1.76M
Nektar Therapeutics NKTR:US USD 77.93M 96.49M
Neurocrine Biosciences NBIX:US USD 300.1M 93.4M
Novartis NOVN:VX USD 10.67B 183M
Pfizer PFE:US USD 19.12B 5.9B
Regeneron Pharmaceuticals REGN:US USD 2.27B 555.1M
Roche Holding ROG:VX 20.75B 3.26B
Sarepta Therapeutics SRPT:US USD 487.06M 42.45M
Tg Therapeutics TGTX:US USD 35.06M 4.48M
Vertex Pharmaceuticals VRTX:US USD 1.21B 117.7M